Trials / Completed
CompletedNCT03737474
A Long-Term Study of Brexpiprazole in Patients With Major Depressive Disorder
A Multi-center, Open-label Trial to Assess the Long-term Safety and Efficacy of Brexpiprazole as Adjunctive Therapy in Patients With Major Depressive Disorder
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 248 (actual)
- Sponsor
- Otsuka Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
This trial is a 52-week study to assess the safety of long-term use of brexpiprazole as adjunctive therapy in combination with an antidepressant.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Brexpiprazole | 2 mg/day (starting dose 1mg/day) of Brexpiprazole will be orally administered once daily |
Timeline
- Start date
- 2018-10-04
- Primary completion
- 2021-03-17
- Completion
- 2021-04-13
- First posted
- 2018-11-09
- Last updated
- 2024-04-29
- Results posted
- 2024-04-29
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT03737474. Inclusion in this directory is not an endorsement.